Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 13Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

HER2-Positive Advanced Biliary Tract Cancer 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × zanidatamab × Gastrointestinal × Clear all
NCT04578444 2025-05-25

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Jazz Pharmaceuticals

No longer available
Gastrointestinal

HER2-Positive Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡